{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T00:15:54Z","timestamp":1789085754165,"version":"build-2803163510"},"reference-count":34,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Pediatric patients with growth hormone deficiency (GHD) are currently treated with daily injections of recombinant human growth hormone (rhGH) to promote linear growth and enable attainment of normal adult height. One of the main reasons for suboptimal growth during rhGH therapy is non-adherence to treatment. The objective of this systematic literature review was to examine the recent literature on pediatric adherence to injectable treatments for chronic conditions (focusing on rhGH) to characterize levels of adherence and identify the factors\/barriers associated with adherence.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The Embase and MEDLINE databases (January 2015\u2013October 2020) were searched to identify publications describing studies of pediatric patients (aged \u226417 years) with GHD and other chronic conditions requiring daily or weekly injectable treatments; a similar targeted search of Chinese literature was also performed. Adherence data were extracted from the included studies and summarized. Risk of bias was determined using the Cochrane Risk of Bias tool 2 or the Newcastle-Ottawa Scale.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 23 publications were included, with all publications except for one (multiple sclerosis) focused on pediatric GHD studies: there were two clinical trials, 18 observational studies and three survey studies. Study sample sizes ranged from 30 to 13,553 patients (median: 95 patients). The definition of adherence varied between studies and included mean adherence rate, median adherence rate, and the percentage of patients within pre-specified adherence categories. Of the publications assessing adherence to daily rhGH, 11 studies reported 12-month mean adherence rate (range: 73.3%\u2013 95.3%) and eight studies reported median adherence (range: 91%\u2013 99.2%). The barriers to treatment adherence identified included self-administration, increased administration frequency, age (adolescence), longer treatment duration, device design, and insufficient family education, awareness, and\/or engagement. Recommendations for increasing adherence included using adherence reminder tools, increasing patient engagement\/education, and improving injection device design and drug product.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Adherence to rhGH treatment was high (&amp;gt;80%) for many studies, though comparability between studies was limited given the substantial heterogeneity in the way adherence was defined, measured, and reported. To address this heterogeneity, we recommend standardizing how adherence is defined and reported and encourage the use of standardized study designs and outcome measures.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fendo.2022.795224","type":"journal-article","created":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:18:15Z","timestamp":1646093895000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":31,"title":["Treatment Adherence to Injectable Treatments in Pediatric Growth Hormone Deficiency Compared With Injectable Treatments in Other Chronic Pediatric Conditions: A Systematic Literature Review"],"prefix":"10.3389","volume":"13","author":[{"given":"Roy","family":"Gomez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. Faisal","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamad","family":"Maghnie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dejun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiaki","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bradley S.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,3,1]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1159\/000350251","article-title":"Understanding the Growth Hormone Therapy Adherence Paradigm: A Systematic Review","volume":"79","author":"Fisher","year":"2013","journal-title":"Horm Res Paediatr"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1136\/adc.2006.105353","article-title":"Facilitating and Understanding the Family\u2019s Choice of Injection Device for Growth Hormone Therapy by Using Conjoint Analysis","volume":"93","author":"Ahmed","year":"2008","journal-title":"Arch Dis Child"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0016223","article-title":"Non-Compliance With Growth Hormone Treatment in Children is Common and Impairs Linear Growth","volume":"6","author":"Cutfield","year":"2011","journal-title":"PloS One"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ghir.2015.12.002","article-title":"Variability in Adherence to rhGH Treatment: Socioeconomic Causes and Effect on Children\u2019s Growth","volume":"26","author":"De Pedro","year":"2016","journal-title":"Growth Horm IGF Res"},{"key":"B5","article-title":"Patient Outcomes in the GHMonitor: The Effect of Delivery Device on Compliance and Growth","author":"Desrosiers","year":"2005","journal-title":"Pediatr Endocrinol Rev"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1159\/000080506","article-title":"Optimizing Growth Hormone Efficacy: An Evidence-Based Analysis","volume":"62","author":"Lustig","year":"2004","journal-title":"Horm Res"},{"key":"B7","doi-asserted-by":"publisher","first-page":"46","DOI":"10.4158\/EP13194.OR","article-title":"Adherence to Growth Hormone Therapy: Results of a Multicenter Study","volume":"20","author":"Aydin","year":"2014","journal-title":"Endocr Pract"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1159\/000493211","article-title":"Identifying Potentially Modifiable Factors Associated With Treatment Non-Adherence in Paediatric Growth Hormone Deficiency: A Systematic Review","volume":"90","author":"Graham","year":"2018","journal-title":"Horm Res Paediatr"},{"key":"B9","unstructured":"GarrittyX\n            GartlehnerG\n            KamelC\n            KingVJ\n            Nussbaumer-StreitB\n            StevensA\n          Cochrane Rapid Reviews. Interim Guidance From the Cochrane Rapid Reviews Methods Group2020"},{"key":"B10","unstructured":"Systematic Reviews: Crd\u2019s Guidance for Undertaking Reviews in Health Care2009"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1007\/s10072-017-3091-6","article-title":"A Multicenter, Observational, Prospective Study of Self- and Parent-Reported Quality of Life in Adolescent Multiple Sclerosis Patients Self-Administering Interferon-Beta1a Using RebiSmart-The FUTURE Study","volume":"38","author":"Ghezzi","year":"2017","journal-title":"Neurol Sci"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.endinu.2018.02.003","article-title":"Adherence to Somatotropin Treatment Administered With an Electronic Device","volume":"65","author":"Arrabal Vela","year":"2018","journal-title":"Endocrinol Diabetes Nutr"},{"key":"B13","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1186\/s12911-020-01183-1","article-title":"Analysis of Real-World Data on Growth Hormone Therapy Adherence Using a Connected Injection Device","volume":"20","author":"Koledova","year":"2020","journal-title":"BMC Med Inform Decis Mak"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgz310","article-title":"Once-Weekly Somapacitan vs Daily GH in Children With GH Deficiency: Results From a Randomized Phase 2 Trial","volume":"105","author":"S\u00e4vendahl","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"B15","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1515\/jpem-2017-0157","article-title":"Adherence to Growth Hormone Therapy in Children and Its Potential Barriers","volume":"31","author":"Mohseni","year":"2018","journal-title":"J Pediatr Endocrinol Metab"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.4158\/EP171786.OR","article-title":"Prevalence and Correlates of Adherence in Children and Adolescents Treated With Growth Hormone: A Multicenter Italian Study","volume":"23","author":"Bagnasco","year":"2017","journal-title":"Endocr Pract"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.23736\/S0391-1977.18.02843-2","article-title":"Monitoring of Treatment Adherence With Easypod in Six Italian Centers: A Real-World Experience","volume":"44","author":"Cardinale","year":"2019","journal-title":"Minerva Endocrinol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1007\/s40618-019-01046-1","article-title":"Adherence to Growth Hormone (GH) Therapy in Naive to Treatment GH-Deficient Children: Data of the Italian Cohort From the Easypod Connect Observational Study (ECOS)","volume":"42","author":"Centonze","year":"2019","journal-title":"J Endocrinol Invest"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1007\/s40618-016-0510-0","article-title":"Adherence in Children With Growth Hormone Deficiency Treated With r-hGH and the Easypod Device","volume":"39","author":"Loche","year":"2016","journal-title":"J Endocrinol Invest"},{"key":"B20","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1186\/s13052-018-0548-z","article-title":"Improvement of Treatment Adherence With Growth Hormone by Easypod Device: Experience of an Italian Centre","volume":"44","author":"Maggio","year":"2018","journal-title":"Ital J Pediatr"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1586\/17434440.2015.1069180","article-title":"A Web-Based Survey Assessing the Impact of Storage Flexibility on the Daily Life of Patients and Caregivers Administering Growth Hormone","volume":"12","author":"Kappelgaard","year":"2015","journal-title":"Expert Rev Med Devices"},{"key":"B22","doi-asserted-by":"publisher","first-page":"e0206009","DOI":"10.1371\/journal.pone.0206009","article-title":"Effect of Adherence to Growth Hormone Treatment on 0-2 Year Catch-Up Growth in Children With Growth Hormone Deficiency","volume":"13","author":"van Dommelen","year":"2018","journal-title":"PloS One"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1530\/EC-18-0172","article-title":"Adherence and Long-Term Growth Outcomes: Results From the Easypod() Connect Observational Study (ECOS) in Paediatric Patients With Growth Disorders","volume":"7","author":"Koledova","year":"2018","journal-title":"Endocr Connect"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1530\/EC-19-0325","article-title":"Adherence and Long-Term Outcomes of Growth Hormone Therapy With Easypod in Pediatric Subjects: Spanish ECOS Study","volume":"8","author":"Rodriguez Arnao","year":"2019","journal-title":"Endocr Connect"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1007\/s40618-020-01218-4","article-title":"Adherence to Treatment in Children With Growth Hormone Deficiency, Small for Gestational Age and Turner Syndrome in Mexico: Results of the Easypod Connect Observational Study (ECOS)","volume":"43","author":"Blanco-Lopez","year":"2020","journal-title":"J Endocrinol Invest"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.ghir.2020.101336","article-title":"Adherence and Long-Term Outcomes of Therapy in Paediatric Patients in Greece Using the Easypod Electromechanical Device for Growth Hormone Treatment: The Phase IV Multicentre Easypod Connect Observational Study (ECOS)","author":"Charmandari","year":"2020","journal-title":"Growth Horm IGF Res"},{"key":"B27","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1159\/000491016","article-title":"Effect of Growth Hormone Therapy on Height Velocity in Korean Children With Idiopathic Short Stature: A Phase III Randomised Controlled Trial","volume":"90","author":"Chung","year":"2018","journal-title":"Horm Res Paediatr"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.4183\/aeb.2020.192","article-title":"COMPLIA: A 12-Month Prospective, Multicentre, Non-Interventional Study to Evaluate Treatment Adherence and Treatment Satisfaction in a Growth Hormone Deficient Paediatric Population Treated With Nutropinaq\u00ae a Somatropin Analogue","volume":"16","author":"Dumitrescu","year":"2020","journal-title":"Acta Endocrinol (Buchar)"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ghir.2018.10.004","article-title":"Long-Term Adherence to Growth Hormone Therapy in a Large Health Maintenance Organization Cohort","volume":"44","author":"Farfel","year":"2019","journal-title":"Growth Horm IGF Res"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1515\/jpem-2017-0146","article-title":"Initial Patient Choice of a Growth Hormone Device Improves Child and Adolescent Adherence to and Therapeutic Effects of Growth Hormone Replacement Therapy","volume":"30","author":"Gau","year":"2017","journal-title":"J Pediatr Endocrinol Metab"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1159\/000437305","article-title":"Low Treatment Adherence in Pubertal Children Treated With Thyroxin or Growth Hormone","volume":"84","author":"Lass","year":"2015","journal-title":"Horm Res Paediatr"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1515\/jpem-2018-0067","article-title":"Improved Adherence and Growth Outcomes With Jet-Delivered Growth Hormone","volume":"32","author":"Michaelidou","year":"2019","journal-title":"J Pediatr Endocrinol Metab"},{"key":"B33","first-page":"18","article-title":"Compliance Analysis of Children\u2019s GHD Treated With PEG rhGH","volume":"20","author":"Li","year":"2020","journal-title":"World Latest Med Inf"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1515\/jpem-2017-0120","article-title":"Individualised Growth Response Optimisation (iGRO) Tool: An Accessible and Easy-to-Use Growth Prediction System to Enable Treatment Optimisation for Children Treated With Growth Hormone","volume":"30","author":"Loftus","year":"2017","journal-title":"J Pediatr Endocrinol Metab"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2022.795224\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:18:19Z","timestamp":1646093899000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2022.795224\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,1]]},"references-count":34,"alternative-id":["10.3389\/fendo.2022.795224"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2022.795224","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,1]]},"article-number":"795224"}}